A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure
Latest Information Update: 09 Apr 2023
At a glance
- Drugs PDC APB (Primary)
- Indications Contact dermatitis
- Focus Adverse reactions
- Sponsors Hapten Sciences
Most Recent Events
- 23 Aug 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
- 23 Aug 2021 Planned primary completion date changed from 1 May 2022 to 1 Nov 2022.
- 23 Aug 2021 Planned initiation date changed from 1 Jul 2021 to 1 Nov 2021.